Discovery of a potent cytotoxic agent that promotes G<sub>2</sub>/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line

Nuth,Manunya; Benakanakere,Manjunatha R.; Ricciardi,Robert P.

doi:10.3892/ijo.2022.5331

Discovery of a potent cytotoxic agent that promotes G₂/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line

Authors:
- Manunya Nuth
- Manjunatha R. Benakanakere
- Robert P. Ricciardi
View Affiliations

Affiliations: Department of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Published online on: February 24, 2022 https://doi.org/10.3892/ijo.2022.5331
Article Number: 41

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Squamous cell carcinoma is the major form of malignancy that arises in head and neck cancer. The modest improvement in the 5‑year survival rate underpins its complex etiology and provides the impetus for the discovery of new therapeutics. The present study describes the discovery of an indole‑based small molecule (24a) that was a potent cytotoxic agent with antiproliferative and pro‑apoptotic properties against a pharyngeal carcinoma cell line, Detroit 562, effectively killing the cells at a half‑maximal inhibitory concentration of 0.03 µM, as demonstrated using cell proliferation studies. The antiproliferative property of 24a was demonstrated by its ability to promote G₂/M blockade, as assessed by cell cycle analysis using flow cytometry and the monitoring of real‑time cell cycle progression by the fluorescence ubiquitination‑based cell cycle indicator. This pro‑apoptotic property is supported by the promotion of TUNEL‑staining and increase in the activities of caspases‑3/7 and ‑6, in addition to the expression of death receptors and the cleavage of poly (ADP‑ribose) polymerase 1 protein as demonstrated by western blotting. Given that Detroit 562 lacks functional p53, it is suggested that 24a acts independently of the tumor suppressor.

View Figures

View References

1	Vigneswaran N and Williams MD: Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 26:123–141. 2014. View Article : Google Scholar : PubMed/NCBI
2	Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA and Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 332:712–717. 1995. View Article : Google Scholar : PubMed/NCBI
3	D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 356:1944–1956. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
5	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
6	Haddad RI and Shin DM: Recent advances in head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
7	Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007. View Article : Google Scholar : PubMed/NCBI
8	Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG and Gutkind JS: The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. Oncotarget. 5:8906–8923. 2014. View Article : Google Scholar : PubMed/NCBI
9	Algazi AP and Grandis JR: Head and neck cancer in 2016: A watershed year for improvements in treatment? Nat Rev Clin Oncol. 14:76–78. 2017. View Article : Google Scholar
10	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
11	Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J, Luginbuhl A, Tuluc M, Campling B and Axelrod R: Current management of locally advanced head and neck cancer: The combination of chemotherapy with locoregional treatments. Semin Oncol. 41:798–806. 2014. View Article : Google Scholar : PubMed/NCBI
12	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hartner L: Chemotherapy for oral cancer. Dent Clin North Am. 62:87–97. 2018. View Article : Google Scholar
14	Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C and Myers JN: Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res. 17:6658–6670. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nuth M, Guan H, Zhukovskaya N, Saw YL and Ricciardi RP: Design of potent poxvirus inhibitors of the heterodimeric processivity factor required for viral replication. J Med Chem. 56:3235–3246. 2013. View Article : Google Scholar : PubMed/NCBI
16	Nuth M, Guan H, Xiao Y, Kulp JL III, Parker MH, Strobel ED, Isaacs SN, Scott RW, Reitz AB and Ricciardi RP: Mutation and structure guided discovery of an antiviral small molecule that mimics an essential C-Terminal tripeptide of the vaccinia D4 processivity factor. Antiviral Res. 162:178–185. 2019. View Article : Google Scholar
17	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
18	Koh SB, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM and Lyons SK: A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level. J Cell Sci. 130:512–520. 2017.
19	Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al: Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 132:487–498. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985. 1993.PubMed/NCBI
21	Chaitanya GV, Alexander JS and Babu PP: PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 8:312010. View Article : Google Scholar : PubMed/NCBI
22	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
23	Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL and Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res. 52:5997–6000. 1992.PubMed/NCBI
24	Giaccia AJ and Kastan MB: The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev. 12:2973–2983. 1998. View Article : Google Scholar : PubMed/NCBI
25	Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805. 2004. View Article : Google Scholar : PubMed/NCBI
26	Deyoung MP and Ellisen LW: p63 and p73 in human cancer: Defining the network. Oncogene. 26:5169–5183. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sniezek JC, Matheny KE, Westfall MD and Pietenpol JA: Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope. 114:2063–2072. 2004. View Article : Google Scholar : PubMed/NCBI
28	Nylander K, Coates PJ and Hall PA: Characterization of the expression pattern of p63α and δnp63α in benign and malignant oral epithelial lesions. Int J Cancer. 87:368–372. 2000. View Article : Google Scholar : PubMed/NCBI
29	Bisso A, Collavin L and Del Sal G: p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des. 17:578–590. 2011. View Article : Google Scholar : PubMed/NCBI
30	el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
31	Georgakilas AG, Martin OA and Bonner WM: p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017. View Article : Google Scholar : PubMed/NCBI
32	Leemans CR, Braakhuis BJM and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar
33	Bailly C, Thuru X and Quesnel B: Combined cytotoxic chemotherapy and immunotherapy of cancer: Modern times. NAR Cancer. 2:zcaa0022020. View Article : Google Scholar : PubMed/NCBI
34	Knox RJ, Friedlos F, Lydall DA and Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-di amminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(ii) differ only in the kinetics of their interaction with dna. Cancer Res. 46:1972–1979. 1986.PubMed/NCBI
35	Boeckman HJ, Trego KS and Turchi JJ: Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res. 3:277–285. 2005. View Article : Google Scholar : PubMed/NCBI
36	Grem JL: 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 18:299–313. 2000. View Article : Google Scholar : PubMed/NCBI
37	Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 7:74362–74379. 2016. View Article : Google Scholar : PubMed/NCBI
38	Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
39	Pendleton KP and Grandis JR: Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck. Clin Med Insights Ther. 2013:10.4137/CMT.S10409. 2013.PubMed/NCBI
40	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
41	Wu GS, Burns TF, McDonald ER III, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
42	Sheikh MS and Fornace AJ Jr: Death and decoy receptors and p53-mediated apoptosis. Leukemia. 14:1509–1513. 2000. View Article : Google Scholar : PubMed/NCBI
43	Hainaut P and Hollstein M: p53 and human cancer: The first ten thousand mutations. Adv Cancer Res. 77:81–137. 2000. View Article : Google Scholar
44	Liu DP, Song H and Xu Y: A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene. 29:949–956. 2010. View Article : Google Scholar :